Literature DB >> 22948864

Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.

Cory Hafer1, Ying Lin, John Kornblum, Franklin D Lowy, Anne-Catrin Uhlemann.   

Abstract

Infections with vancomycin-intermediate Staphylococcus aureus (VISA) have been associated with vancomycin treatment failures and poor clinical outcomes. Routine identification of clinical isolates with increased vancomycin MICs remains challenging, and no molecular marker exists to aid in diagnosis of VISA strains. We tested vancomycin susceptibilities by using microscan, Etest, and population analyses in a collection of putative VISA, methicillin-resistant S. aureus, and methicillin-sensitive S. aureus (VSSA) infectious isolates from community- or hospital-associated S. aureus infections (n = 77) and identified 22 VISA and 9 heterogeneous VISA (hVISA) isolates. Sequencing of VISA candidate loci vraS, vraR, yvqF, graR, graS, walR, walK, and rpoB revealed a high diversity of nonsynonymous single-nucleotide polymorphisms (SNPs). For vraS, vraR, yvqF, walK, and rpoB, SNPs were more frequently present in VISA and hVISA than in VSSA isolates, whereas mutations in graR, graS, and walR were exclusively detected in VISA isolates. For each of the individual loci, SNPs were only detected in about half of the VISA isolates. All but one VISA isolate had at least one SNP in any of the genes sequenced, and isolates with an MIC of 6 or 8 μg/ml harbored at least 2 SNPs. Overall, increasing vancomycin MICs were paralleled by a higher proportion of isolates with SNPs. Depending on the clonal background, SNPs appeared to preferentially accumulate in vraS and vraR for sequence type 8 (ST8) and in walK and walR for ST5 isolates. Taken together, by comparing VISA, hVISA, and VSSA controls, we observed preferential clustering of SNPs in VISA candidate genes, with an unexpectedly high diversity across these loci. Our results support a polygenetic etiology of VISA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22948864      PMCID: PMC3486570          DOI: 10.1128/AAC.01139-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009.

Authors:  Victor D Rosenthal; Dennis G Maki; Silom Jamulitrat; Eduardo A Medeiros; Subhash Kumar Todi; David Yepes Gomez; Hakan Leblebicioglu; Ilham Abu Khader; María Guadalupe Miranda Novales; Regina Berba; Fernando Martín Ramírez Wong; Amina Barkat; Osiel Requejo Pino; Lourdes Dueñas; Zan Mitrev; Hu Bijie; Vaidotas Gurskis; S S Kanj; Trudell Mapp; Rosalía Fernández Hidalgo; Nejla Ben Jaballah; Lul Raka; Achilleas Gikas; Altaf Ahmed; Le Thi Anh Thu; María Eugenia Guzmán Siritt
Journal:  Am J Infect Control       Date:  2010-03       Impact factor: 2.918

2.  Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.

Authors:  Miki Matsuo; Tomomi Hishinuma; Yuki Katayama; Longzhu Cui; Maria Kapi; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

3.  walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.

Authors:  Mitsutaka Shoji; Longzhu Cui; Risa Iizuka; Akira Komoto; Hui-min Neoh; Yukiko Watanabe; Tomomi Hishinuma; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

4.  Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus.

Authors:  Yukiko Watanabe; Longzhu Cui; Yuki Katayama; Kishii Kozue; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2011-04-27       Impact factor: 5.948

5.  Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR.

Authors:  Yoshihisa Kato; Takahisa Suzuki; Takashi Ida; Kazunori Maebashi
Journal:  J Antimicrob Chemother       Date:  2010-01       Impact factor: 5.790

6.  Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Hui-min Neoh; Mitsutaka Shoji; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

7.  Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus.

Authors:  M C Enright; N P Day; C E Davies; S J Peacock; B G Spratt
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

8.  Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.

Authors:  Susana Gardete; Choonkeun Kim; Boris M Hartmann; Michael Mwangi; Christelle M Roux; Paul M Dunman; Henry F Chambers; Alexander Tomasz
Journal:  PLoS Pathog       Date:  2012-02-02       Impact factor: 6.823

9.  The environment as an unrecognized reservoir for community-associated methicillin resistant Staphylococcus aureus USA300: a case-control study.

Authors:  Anne-Catrin Uhlemann; Justin Knox; Maureen Miller; Cory Hafer; Glenny Vasquez; Megan Ryan; Peter Vavagiakis; Qiuhu Shi; Franklin D Lowy
Journal:  PLoS One       Date:  2011-07-26       Impact factor: 3.240

10.  Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.

Authors:  Benjamin P Howden; Christopher R E McEvoy; David L Allen; Kyra Chua; Wei Gao; Paul F Harrison; Jan Bell; Geoffrey Coombs; Vicki Bennett-Wood; Jessica L Porter; Roy Robins-Browne; John K Davies; Torsten Seemann; Timothy P Stinear
Journal:  PLoS Pathog       Date:  2011-11-10       Impact factor: 6.823

View more
  44 in total

Review 1.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

2.  Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Mélanie Roch; Perrine Clair; Adriana Renzoni; Marie-Elisabeth Reverdy; Olivier Dauwalder; Michèle Bes; Annie Martra; Anne-Marie Freydière; Frédéric Laurent; Philippe Reix; Oana Dumitrescu; François Vandenesch
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 3.  New Threats from an Old Foe: Methicillin-Resistant Staphylococcus aureus Infections in Neonates.

Authors:  Ying Dong; Kirsten Glaser; Christian P Speer
Journal:  Neonatology       Date:  2018-05-25       Impact factor: 4.035

4.  Reduced Vancomycin Susceptibility of Methicillin-Susceptible Staphylococcus aureus Has No Significant Impact on Mortality but Results in an Increase in Complicated Infection.

Authors:  Sean B Sullivan; Eloise D Austin; Stephania Stump; Barun Mathema; Susan Whittier; Franklin D Lowy; Anne-Catrin Uhlemann
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 5.  Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance.

Authors:  Daina Zeng; Dmitri Debabov; Theresa L Hartsell; Raul J Cano; Stacy Adams; Jessica A Schuyler; Ronald McMillan; John L Pace
Journal:  Cold Spring Harb Perspect Med       Date:  2016-12-01       Impact factor: 6.915

6.  VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.

Authors:  Yuanyuan Dai; Wenjiao Chang; Changcheng Zhao; Jing Peng; Liangfei Xu; Huaiwei Lu; Shusheng Zhou; Xiaoling Ma
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

7.  Induction of Immunosuppressive CD8+CD25+FOXP3+ Regulatory T Cells by Suboptimal Stimulation with Staphylococcal Enterotoxin C1.

Authors:  Juyeun Lee; Nogi Park; Joo Youn Park; Barbara L F Kaplan; Stephen B Pruett; Juw Won Park; Yong Ho Park; Keun Seok Seo
Journal:  J Immunol       Date:  2017-12-13       Impact factor: 5.422

8.  Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.

Authors:  Celine Vidaillac; Susana Gardete; Ryan Tewhey; George Sakoulas; Glenn W Kaatz; Warren E Rose; Alexander Tomasz; Michael J Rybak
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

Review 9.  [Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].

Authors:  Sandra Rincón; Diana Panesso; Lorena Díaz; Lina P Carvajal; Jinnethe Reyes; José M Munita; César A Arias
Journal:  Biomedica       Date:  2014-04       Impact factor: 0.935

10.  Genome sequence-based discriminator for vancomycin-intermediate Staphylococcus aureus.

Authors:  Lavanya Rishishwar; Robert A Petit; Colleen S Kraft; I King Jordan
Journal:  J Bacteriol       Date:  2013-12-20       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.